U.S.-based pharmaceutical giant German biotech company BioNTech were already collaborating to come up with a flu vaccine ...
Zacks Investment Research on MSN
Pfizer stock slides despite Q4 earnings beat and new obesity drug data
Pfizer PFE reported fourth-quarter 2025 adjusted earnings per share of 66 cents, which comprehensively beat the Zacks ...
Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...
Hosted on MSN
Pfizer Stock Slips Premarket Despite Completing Metsera Deal; Investors React To BioNTech Stake Cut
・The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3. ・Pfizer’s BioNTech position was reduced by 54.7%, leaving ...
Add Yahoo as a preferred source to see more of our stories on Google. A vial of the Pfizer/BioNTech Comirnaty vaccine against Covid-19 at a mass vaccination center on July 1, 2021 in Leipzig, Germany.
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results